CERVAVAC

Cervavac is a 4-valent recombinant HPV vaccine designed to protect boys and girls aged 9-26 years against Human Papillomavirus (HPV) strains 6, 11, 16, and 18. These HPV strains are responsible for causing cervical, vulvar, vaginal, anal, oropharyngeal, and other head and neck cancers, as well as genital warts and precancerous lesions. Cervavac offers comprehensive protection against some of the most common and dangerous HPV-related diseases. Cervavac protects against multiple HPV-related cancer

• ✓India's first indigenously developed 4-valent HPV vaccine by Serum Institute
• ✓Protects against HPV strains 6, 11, 16, and 18 responsible for cervical cancer and genital warts
• ✓Recommended for boys and girls aged 9 to 26 years
• ✓Reduces risk of cervical, vulvar, vaginal, anal, and oropharyngeal cancers

Requires 3 doses